Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus placebo in moderate Crohn's disease
2012-004222-25Phase 3Terminated
- Sponsor
- AB Science
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of masitinib in Crohn's disease (4 arms), sponsored by AB Science. Primary endpoint: Enhanced clinical response at week 12. Started Jan 2013; status: terminated.
02
Drugs
masitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2012-004222-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004222-25.